Senior Burnet researchers selected for prestigious AAHMS mentoring program
Improved maternal health outcomes in Burnet modelling for Gates Foundation
Burnet researchers receive $5 million in NHMRC grants
UN High Level Meeting a prime opportunity to end TB
Research Reports + Policy Briefs
IMPACT Magazine
Events
Research Articles
How Science Matters Podcast
Study at Burnet
"It is still very little; I cannot pass it on": a qualitative study of experienc...
Police drug seizures cannot solve the problem of toxic drug supply in North Amer...
The unfinished agenda of communicable diseases among children and adolescents be...
Robust immunity to influenza vaccination in haematopoietic stem cell transplant ...
Vaccines
Diagnostics
Therapeutics
Antibody Platforms
Australia
Papua New Guinea
Myanmar
People of Burnet
Leadership
Burnet Partners
Board Members
Current Appeal
Donating for Individuals
Trusts + Foundations
Corporate Supporters
Giving in Wills + Bequests
Supporter Stories
About Us
Careers
History
Annual + Financial Reports
Explore our research reports and policy briefs, designed to explain key findings of our work clearly and provide recommendations for government, community organisations and policymakers alike.
For peer reviewed publications, see: Research Articles
Even a partially effective hepatitis C vaccine could effectively complement existing treatments to r...
Significant and ongoing Burnet Institute research has provided important insights into the social ne...
Gender and genetics could identify people who are more likely to eliminate hepatitis C after reinfec...
Hepatitis C testing in people who inject drugs should be combined with harm reduction counselling to...
Targeting social networks with a ‘treat your friends’ approach is a feasible, practical and effectiv...
Elimination of hepatitis C requires effective engagement of people who inject drugs. A targeted comp...
Genetic signatures of the hepatitis C virus demonstrate the important role of injecting networks in ...
Modest increases in hepatitis C treatment rates amongst people who inject drugs will significantly r...
Evidence supports treatment (pegylated interferon plus ribavirin) of hepatitis C in people who injec...
